Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Intermediate-risk acute myeloid leukemia therapy: current and future.

Hematology. American Society of Hematology. Education Program - 5 Dec 2014

Döhner Konstanze, Paschka Peter

Abstract excerpt

In recent years, research in molecular genetics has been instrumental in deciphering the molecular heterogeneity of acute myeloid leukemia (AML), in particular the subset of patients with "intermediate-risk" cytogenetics. However, at present, only the markers NPM1, CEBPA, and FLT3 have entered clinical practice. Treatment of intermediate-risk AML patients eligible for intensive therapy has not changed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytogenetics
Share to NPM1 gene
Share to Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Biology

Share to Mutation

Share to Nucleophosmin

Share to Risk Factors

Share to Survival Analysis

Source

Identifiers

PMID: 25696832
DOI: 10.1182/asheducation-2014.1.34

Genes

FLT3
NPM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Intermediate-risk acute myeloid leukemia therapy: current and future.PMID 25696832Read ↗

Evolving treatment strategies in patients with high-risk acute myeloid leukemia.Semantic proximity Read ↗

Prognosis and treatment in acute myeloid leukemia: a comprehensive reviewSemantic proximity Read ↗

Mutational spectrum and prognostic stratification of intermediate-risk acute myeloid leukemia.Semantic proximity Read ↗

Treatment Approaches in Pediatric Acute Myeloid Leukemia: A Narrative ReviewSemantic proximity Read ↗

A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice.Semantic proximity Read ↗

Diagnosis and Therapy of Acute Myeloid Leukemia in the Era of Molecular Risk Stratification.Semantic proximity Read ↗

Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.Semantic proximity Read ↗

Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial.Semantic proximity Read ↗

Management of patients with cytogenetically normal acute myeloid leukemia who have neither favorable nor unfavorable markers.Semantic proximity Read ↗

Moving toward individualized target-based therapies in acute myeloid leukemia.Semantic proximity Read ↗

Acute myeloid leukemia: 2013 update on risk‐stratification and managementSemantic proximity Read ↗

Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and managementSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.